Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 80 /hr

★★★★★

☆☆☆☆☆

Hire Luka B.

United States

USD 80 /hr

Biostatistician & Finance Consultant | CFA, ASA, CICPA

Profile Summary

I am a biostatistician and investment professional with a unique interdisciplinary background spanning Medicine, Biostatistics, and Finance. Holding a Master’s degree in Biostatistics from Fudan University, a Bachelor of Medicine, and three premier professional designations—CFA (Chartered Financial Analyst), ASA (Associate of the Society of Actuaries), and CICPA (Certified Public Accountant)—I bridge the gap between complex clinical data and strategic financial decisions. With over 3 years of experience in healthcare investment banking and private equity asset management, I help medical researchers, biotech startups, and investment firms translate scientific data into rigorous analytical models and commercial insights. Core Services Offered: 1. Biostatistics & Medical Data Analysis Clinical Trial & Research Data Analysis: Proficient in using R and Python for processing, analyzing, and validating clinical research datasets[1][2]. Predictive Modeling: Developing predictive models and survival analysis (e.g., nomograms)[3]. Scientific Publication Support: Experienced in drafting and reviewing statistical sections for peer-reviewed journals. I have co-authored 5 SCI-indexed papers in oncology and clinical medicine (Impact Factors up to 11.6). 2. Healthcare Financial Analysis & Market Due Diligence Financial Modeling & Valuation: Building complex DCF, LBO, and sensitivity analysis models tailored to healthcare and biotech assets. Commercialization & Pipeline Assessment: Utilizing medical and biostatistics expertise to review clinical trial data and evaluate the market success rates of pipeline drugs or medical devices[4]. Investment Memos & Reports: Drafting investment evaluation reports, market entry strategies, and risk warning reports in professional English. Whether you need rigorous statistical validation for your medical research[1] or deep-dive financial analysis for a healthcare venture, I deliver balanced, data-driven solutions.

Subject Matter Expertise

• ☆ Biostatistics
• ☆ SPSS
• ☆ Excel
• ☆ STATA
• ☆ R
• ☆ Investment Management

Services

• Writing
• Research
• Consulting
• Data & AI

Writing Medical Writing

Research Meta-Research

Consulting Digital Strategy Consulting, Healthcare Consulting, Scientific and Technical Consulting

Data & AI Predictive Modeling, Statistical Analysis, Data Visualization, Big Data Analytics

Work Experience

Fudan University

- Present

PE Investment manager

Mid-sized Life Insurance Group (Asset Management)

July 2025 - Present

Education

Master (Life Science)

Fudan University

September 2019 - June 2022

Bachelor (Public Health)

Southeast University

September 2014 - June 2019

Certifications

• CICPA

  The Chinese Institute of Certified Public Accountants

  February 2026 - Present

• ASA

  Society of Actuaries

  January 2024 - December 2026

• CFA

  Institute of CFA

  July 2024 - July 2026

Publications

JOURNAL ARTICLE

Wei Shuyao, Bao Mingyang, Ma Feifei, Ha Xiaoqin (2022). CK19 Predicts Recurrence and Prognosis of HBV Positive HCC . Journal of Gastrointestinal Surgery.

Jiaojiao Xie, Ding Shi, Mingyang Bao, Xiaoyi Hu, Wenrui Wu, Jifang Sheng, Kaijin Xu, Qing Wang, Jingjing Wu, Kaicen Wang, et al. (2022). A Predictive Nomogram for Predicting Improved Clinical Outcome Probability in Patients with COVID-19 in Zhejiang Province, China . Engineering.

Mingyang Bao, Qiuyu Zhu, Tuerganaili Aji, Shuyao Wei, Talaiti Tuergan, Xiaoqin Ha, Alimu Tulahong, Xiaoyi Hu, Yueqing Hu (2021). Development of Models to Predict Postoperative Complications for Hepatitis B Virus-Related Hepatocellular Carcinoma . Frontiers in Oncology.

Xiaoyi Hu, Mingyang Bao, Jiacheng Huang, Lin Zhou, Shusen Zheng (2020). Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma . Frontiers in Oncology.

Mingyang Bao, Lihua Zhang, Yueqing Hu (2020). Novel gene signatures for prognosis prediction in ovarian cancer . Journal of Cellular and Molecular Medicine.

Mingyang Bao, Lina Wang (2020). The longitudinal trend of hypertension prevalence in Chinese adults from 1959 to 2018: a systematic review and meta-analysis . Annals of Palliative Medicine.

Shan Lu, Ming-Yang Bao, Shu-Mei Miao, Xin Zhang, Qing-Qing Jia, Shen-Qi Jing, Tao Shan, Xiao-Hong Wu, Yun Liu (2019). Prevalence of hypertension, diabetes, and dyslipidemia, and their additive effects on myocardial infarction and stroke: a cross-sectional study in Nanjing, China . Annals of Translational Medicine.